20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.
20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.
Further long-term data demonstrate continuing, clinically meaningful efficacy at all time-points measured out to 18 months post-treatment
25 June 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a new research evaluation agreement with a major US biotechnology company in connection with the use of the Company’s proprietary exosomes for the delivery of novel gene silencing therapeutics.
17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.
Newly published positive efficacy data in an accepted model of Huntington’s disease
07 April 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company’s proprietary exosomes to deliver novel therapeutics.
Meaningful clinical effect observed in patients out to 12 months post-treatment
17 February 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.
New data show ReNeuron’s lead CTX cell therapy candidate can be
re-programmed into a pluripotent state and differentiated into other cell types
“Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa